Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$642 Sell
18
-530
-97% -$16.8K ﹤0.01% 3252
2026
Q2
$15.1K Sell
548
-20,825
-97% -$553K ﹤0.01% 2153
2026
Q1
$573K Buy
21,373
+3,747
+21% +$112K 0.03% 519
2025
Q4
$543K Buy
17,626
+17,616
+176,160% +$549K 0.02% 526
2025
Q3
$307 Buy
+10
New +$244 ﹤0.01% 2796

Other funds holding GMAB

BFC Planning's GMAB Position: Q3 2026 in Review

BFC Planning reduced its Genmab (GMAB) stake by 97% in Q3 2026, selling an estimated $16.8K and leaving 18 shares worth $642. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

BFC Planning first reported a position in GMAB in Q3 2025 and has held it in 5 quarters since. The position peaked at $573K in Q1 2026. 258 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • BFC Planning held 18 shares of Genmab worth $642 as of Q3 2026.
  • BFC Planning sold 530 Genmab shares in Q3 2026, an estimated $16.8K.
  • Genmab made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3252 holding.
  • BFC Planning first reported a position in Genmab in Q3 2025 and has held it in 5 quarters since.
  • BFC Planning's Genmab position peaked at $573K in Q1 2026.
  • 258 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.